Source:http://linkedlifedata.com/resource/pubmed/id/17982493
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0013018,
umls-concept:C0035648,
umls-concept:C0205099,
umls-concept:C0205171,
umls-concept:C0392756,
umls-concept:C0441800,
umls-concept:C0445356,
umls-concept:C0522510,
umls-concept:C0856825,
umls-concept:C1504389,
umls-concept:C1515895,
umls-concept:C1527169,
umls-concept:C2603343
|
| pubmed:issue |
4
|
| pubmed:dateCreated |
2008-2-27
|
| pubmed:abstractText |
We analysed factors associated with moderate to severe acute GVHD in 111 patients treated with fludarabin-based reduced intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). Most patients had a haematological malignancy. Donors were 97 HLA-A, -B and -DRbeta1 identical unrelated and 14 HLA-A, -B or -DRbeta1 allele mismatched unrelated donors. In the univariate analysis, we found ten factors associated with acute GVHD. These were diagnosis (P=0.06), GVHD prophylaxis with combinations other than CsA+MTX (P=0.006), graft nucleated (P<0.001) and CD34 (P<0.001) cell-dose, bidirectional ABO mismatch (P=0.001), conditioning (P=0.002), hospital vs home-care (P=0.06), ATG dose (P<0.001), donor herpes virus serology (P=0.07) and an immunized female donor to male recipient (P=0.05). In the multivariate analysis, three factors remained significant: a high CD34 cell dose (P<0.001), low dose (4 mg/kg) ATG (P<0.001), and an immunized female donor to male recipient (P<0.01). Patients receiving a CD34 cell dose > or =17.0 x 10(6) per kg had a higher incidence of GVHD, 53.7%, compared to 22.3% in patients receiving a lower dose (P=0.002). In patients without any of these risk factors (n=70), the incidence of acute GVHD was 14.1%, while it was 38.0 and 85.0% in patients with one (n=29) or two (n=10) risk factors (P<0.001). We concluded that risk factors for acute GVHD using RIC are similar as using myeloablative conditioning.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
399-405
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17982493-Adolescent,
pubmed-meshheading:17982493-Adult,
pubmed-meshheading:17982493-Aged,
pubmed-meshheading:17982493-Child,
pubmed-meshheading:17982493-Child, Preschool,
pubmed-meshheading:17982493-Female,
pubmed-meshheading:17982493-Graft vs Host Disease,
pubmed-meshheading:17982493-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17982493-Humans,
pubmed-meshheading:17982493-Infant,
pubmed-meshheading:17982493-Kaplan-Meier Estimate,
pubmed-meshheading:17982493-Male,
pubmed-meshheading:17982493-Middle Aged,
pubmed-meshheading:17982493-Retrospective Studies,
pubmed-meshheading:17982493-Risk Factors,
pubmed-meshheading:17982493-Tissue Donors,
pubmed-meshheading:17982493-Transplantation, Homologous,
pubmed-meshheading:17982493-Transplantation Conditioning
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
|
| pubmed:affiliation |
Department of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. mats.remberger@ki.se
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|